Evidence map›Paper›PMID 39600699›Full record

ArticleFrontiers in immunology2024

Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.

Xiaojuan Ma, Shuang Zhang, Xiaochen Ren, Yujie Feng, Hui Li, Shi Chen, Jingen Xu, Yanting Wang, Guo-Yuan Peng, Qingran Yan and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Xiaojuan Ma *Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
Shuang Zhang *Department of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaochen Ren *Department of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yujie FengDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Hui LiDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Shi ChenDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Jingen XuDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yanting WangDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Guo-Yuan PengDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Qingran YanRheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
Huifeng JiaDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Simin XiaDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaopei CuiDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaofang ChenDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xianfei PanDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Shaojie WangDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Haijia YuDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiaoyue WeiDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Mingwei LiDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Bei LiuRheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
Jingyue XuDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Qiaoxia QianDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Xiangyang ZhuDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Yifan ZhanDepartment of Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
Liangjing LuRheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody drugs targeting single inflammatory cytokines have revolutionized the treatment of immune-mediated inflammatory diseases. To investigate whether dual targeting interleukin-17 (IL-17) and IL-36 enhances anti-inflammatory activity, bispecific Ab HB0043 was generated by linking the single chain fragment variables (scFvs) from humanized anti-IL-36R antibody (HB0034) to the C-terminus of the heavy chain of anti-IL-17A IgG1 (HB0017) Fc using a flexible peptide linker. HB0043 largely maintained the binding affinities and biological activities of the two parent monoclonal antibodies (mAbs)

Indexed as

Antibodies, BispecificAnti-Inflammatory AgentsInterleukin-1Interleukin-17AnimalsDisease Models, AnimalFibroblastsHumansImiquimodMacaca fascicularisMiceSignal TransductionAntibodies, BispecificAnti-Inflammatory AgentsIL17A protein, humanImiquimodInterleukin-1Interleukin-17bispecific antibodyIL-17AIL-36Rskin fibrosisskin inflammation

Identifiers

PMID39600699
PMCPMC11590123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.